Marine Natural Products with Anti-obesity and Antidiabetic Potentials
A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".
Deadline for manuscript submissions: closed (1 March 2024) | Viewed by 1505
Special Issue Editor
Interests: Type 2 diabetes; obesity; animal model; nutrition; functional foods; medicinal foods; medicinal plants; artificial sweeteners; natural sweeteners
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Obesity and diabetes represent serious threats to the global health system due to their rapid increase in prevalence all over the world. Projections suggest that the current number of overweight and obese people will double by 2030. Additionally, obesity is one of the major causal factors for the development of insulin resistance as well as type 2 diabetes, hence the term ‘diabesity’, which refers to the occurrence of diabetes as a result of obesity. ‘Diabesity’ is associated with the development and progression of other noncommunicable diseases, including but not limited to cardiovascular disease, hypertension, and stroke. There are a number of oral medicines available for obesity and diabetes; however, none of these are without side effects, and all need to be used in conjunction with being physically active and consuming a healthy balanced diet. Almost all these conventional medicines are also not affordable for people in underdeveloped and developing countries. Hence, the demand for natural anti-obesity and antidiabetic medicines has increased in the recent years due to their fewer or no side effects and lower cost. A large number of marine algae on the coastline goes to waste with no valuable use, although there are reports on the potential anti-obesity and antidiabetes activities of marine algae and their bioactive compounds.
Hence, you are invited to submit your original or review articles based on the anti-obesity and antidiabetes effects of marine algae, and their isolated bioactive compounds which were developed based on the in vitro, ex vivo, in vivo (animal model) and clinical trials, and their mechanism of actions behind the biological effects.
Prof. Dr. Md. Shahidul Islam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
